Risk Factors of Daptomycin-Induced Eosinophilic Pneumonia in a Population with Osteoarticular Infection

被引:14
|
作者
Soldevila-Boixader, Laura [1 ,2 ]
Villanueva, Bernat [1 ]
Ulldemolins, Marta [1 ]
Benavent, Eva [1 ,2 ]
Padulles, Ariadna [3 ]
Ribera, Alba [1 ,2 ]
Borras, Irene [1 ]
Ariza, Javier [1 ,2 ,4 ]
Murillo, Oscar [1 ,2 ,4 ]
机构
[1] IDIBELL Hosp Univ Bellvitge, Infect Dis Serv, Feixa Llarga S-N, Barcelona 08907, Spain
[2] Bone & Joint Infect Study Grp Spanish Soc Clin Mi, Madrid 28003, Spain
[3] IDIBELL Hosp Univ Bellvitge, Pharm Dept, Feixa Llarga S-N, Barcelona 08907, Spain
[4] Inst Salud Carlos III, Spanish Network Res Infect Dis REIPI RD16 0016 00, Madrid 28029, Spain
来源
ANTIBIOTICS-BASEL | 2021年 / 10卷 / 04期
关键词
daptomycin; eosinophilic pneumonia; risk factors; PROSTHETIC JOINT INFECTION; EFFICACY; RIFAMPIN; SAFETY; BONE;
D O I
10.3390/antibiotics10040446
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Daptomycin-induced eosinophilic pneumonia (DEP) is a rare but severe adverse effect and the risk factors are unknown. The aim of this study was to determine risk factors for DEP. Methods: A retrospective cohort study was performed at the Bone and Joint Infection Unit of the Hospital Universitari Bellvitge (January 2014-December 2018). To identify risk factors for DEP, cases were divided into two groups: those who developed DEP and those without DEP. Results: Among the whole cohort (n = 229) we identified 11 DEP cases (4.8%) and this percentage almost doubled in the subgroup of patients >= 70 years (8.1%). The risk factors for DEP were age >= 70 years (HR 10.19, 95%CI 1.28-80.93), therapy >14 days (7.71, 1.98-30.09) and total cumulative dose of daptomycin >= 10 g (5.30, 1.14-24.66). Conclusions: Clinicians should monitor cumulative daptomycin dosage to minimize DEP risk, and be cautious particularly in older patients when the total dose of daptomycin exceeds 10 g.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Daptomycin-induced eosinophilic pneumonia: Are there any risk factors?
    Ahouansou, Nelly
    Georges, Marjolaine
    Beltramo, Guillaume
    Aswad, Nicolas
    Hassani, Yasmina
    Bonniaud, Philippe
    INFECTIOUS DISEASES NOW, 2021, 51 (07): : 618 - 621
  • [2] Factors Associated with Daptomycin-Induced Eosinophilic Pneumonia
    Ishikawa, Kazuhiro
    Matsuo, Takahiro
    Tsuda, Yasumasa
    Rahman, Mahbubur
    Uehara, Yuki
    Mori, Nobuyoshi
    ANTIBIOTICS-BASEL, 2022, 11 (02):
  • [3] Daptomycin-Induced Eosinophilic Pneumonia
    Brixey, A. G.
    Willers, E. D.
    Ferrell, P. B.
    Light, R. W.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
  • [4] Daptomycin-induced eosinophilic pneumonia
    Roux, Sandrine
    Ferry, Tristan
    Chidiac, Christian
    Valour, Florent
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2015, 37 : 95 - 96
  • [5] Daptomycin-Induced Eosinophilic Pneumonia
    Chan, R.
    Sakhamuri, P.
    Walker, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [6] Daptomycin-induced eosinophilic pneumonia
    Hassett, Michael R.
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2024, 37 (04): : 4 - 4
  • [7] Daptomycin-Induced Eosinophilic Pneumonia
    Riehani, A.
    Cooke, G.
    Stewart, J.
    Sharma, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [8] DAPTOMYCIN-INDUCED ACUTE EOSINOPHILIC PNEUMONIA
    Chilingarashvili, Giorgi
    Mohan, Arjunmohan
    Lazar, Roxana
    CHEST, 2024, 166 (04) : 3473A - 3474A
  • [9] THE CASE OF DAPTOMYCIN-INDUCED EOSINOPHILIC PNEUMONIA
    Gerts, Neil
    Nathan, Ramesh
    Takher, Jasprit
    CHEST, 2023, 164 (04) : 3325A - 3326A
  • [10] Daptomycin-Induced Acute Eosinophilic Pneumonia
    Portalatin, Gilda M.
    Chin, Jodi-Ann
    Foster, Brian
    Perry, Kevin
    McWilliams, Carla
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (02)